Goal-directed vs. Empirical Tranexamic Acid Administrationin Cardiovascular Surgery

Launched by KONKUK UNIVERSITY MEDICAL CENTER · Mar 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the best way to give a medication called tranexamic acid (TXA) during heart surgery to reduce bleeding after the operation. There are two methods being compared: one where TXA is given based on a standard approach, and another where it is given based on specific tests that check how the blood is clotting. The goal is to see if the test-based approach is as effective as the standard one in minimizing bleeding and other complications, such as blood clots and seizures.

To participate in this trial, patients need to be scheduled for elective heart surgery that uses a heart-lung machine and must agree to the study by signing a consent form. Some people may not be eligible, including those who are pregnant, refuse blood transfusions, or have certain medical conditions like a history of blood clots or seizures. If you join the study, you will be monitored after your surgery to assess how well the TXA is working and to check for any side effects. This research aims to improve patient outcomes in heart surgery by finding the safest and most effective way to manage bleeding.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients who will undergo elective cardiovascular surgery employing cardiopulmonary bypass
• • patients who provide written informed consent
• Exclusion Criteria:
• • pregnancy
• • refusal of allogenic blood transfusion
• • taking thrombin
• • history of thromboembolic and familial hypercoagulability disease
• • recent history of myocardial infarction or ischemic cerebral infarction (within 90 days)
• • hypersensitive to TXA
• • histroy of convulsion or epilepsy
• • taking hemodialysis
• • history of Heparin-induced thrombocytopenia